AcornMed is committed to the early diagnosis and screening of urological cancer. We invite companies with excellent products to collaborate with in advancing the clinical registration and commercialization of these products in China.

We have developed high-performance products like AcornUI-SEEK for early diagnosis of urothelial carcinoma, AcornUI-MRD for postoperative recurrence monitoring, and AcornUPro-SEEK for early prostate cancer screening. We are looking forward to finding overseas partners to collaborate on the clinical registration and commercial promotion of these products in their respective markets.

Additionally, we have collaborated with renowned Chinese innovative pharmaceutical companies and global industry leaders, such as Jiangsu Hengrui Pharmaceuticals Co., Ltd., CSPC Pharmaceutical Group Limited, Innocare Pharma Limited, AstraZeneca, and Johnson & Johnson. We offer advanced technical platforms including NGS, qPCR, ddPCR and pathological immunohistochemistry. Overseas pharmaceutical companies seeking drug registration in China are invited to collaborate with us. We can serve as a central laboratory providing testing services and as a strategic partner in developing companion diagnostic kits, facilitating market entry and sales of drugs in China.

We hope to establish strategic partnerships with leading enterprises worldwide focused on early diagnosis and screening of urological cancer in order to develop exceptional products, leverage each other's strengths, and address unmet clinical needs for patients around the world.